Skip to content

Microcirculatory Alteration and Biomarkers: New Approach for Early Assessment of Septic Multi-organ Dysfunction

Microcirculatory Alteration and Biomarkers: New Approach for Early Assessment of Septic Multi-organ Dysfunction

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02426645
Enrollment
25
Registered
2015-04-27
Start date
2015-04-30
Completion date
2019-04-30
Last updated
2018-05-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Organ Failure, Sepsis

Keywords

Biomarkers, Sepsis, Multi organ dysfunction, Immunomonitoring, CEUS

Brief summary

The aim of this study is to investigate associations between early structural cellular injury and microvascular alteration with progression of septic organ dysfunction according to total SOFA-Score (an ICU-scoring system - the Sequential Organ Failure Assessment Score). Patients will be monitored for renal (TIMP-2, IGFBP7), and intestinal biomarkers (plasma i-FABP) in conjunction with kidney and muscle vascular bed microvascular perfusion analysis assessed by contrast-enhanced ultrasonography (CEUS). In parallel, a comprehensive analysis of patients' immunological status will be conducted using an established, on-site immune monitoring panel. The ultimate goal of this study is an early identification of septic patients developing multiorgan dysfunction which may facilitate a timely novel intervention in the future to improve outcome.

Interventions

None listed

Sponsors

Prof. Dr. Marc-H. Dahlke, Ph. D.
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Patients ≥18 years of age with severe sepsis and fulfill the following criteria at the admission to ICU: * Peritonitis (abdominal infection) and performed source control (either surgically or interventionally) * 2 or more criteria for systemic inflammatory response syndrome (temperature \>38° or\<36°; heart rate \>90 beats per minute; respiratory rate \>20 breaths per minute or paCO2 \<32 mmHg; white blood cell count \>12,000/mm3, \<4000mm3 or \>10% immature forms) and serum lactate level of 4mmol/l and more or refractory hypotension - mean arterial pressure \<65mmHg or systolic blood pressure \<90mmHg after fluid challenge of 1000ml or more /30min * Absence of any familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule * Written informed consent prior to any study procedures

Exclusion criteria

* Pre-existing renal-replacement therapy in the pre-operative course * Pre-existing shock * Acute coronary syndrome * Active hemorrhage * Trauma * Known allergy to ultrasound contrast media * Anemia with hemoglobin concentration \< 7g/dl * Patients not able to give written informed consent

Design outcomes

Primary

MeasureTime frame
Assessment of early post-operative course of novel cellular injury biomarkers as well as microvascular perfusion in critically ill patients with severe sepsis and to collection any first evidence of the association of these markers with the SOFA-Score60 weeks

Secondary

MeasureTime frameDescription
90 day mortality60 weeks
Length of ICU stay60 weeks
Length of hospital stay60 weeks
Early post-operative course of microvascular perfusion of the kidney and muscle vasculature bed using CEUS60 weeks
28 day mortality60 weeks
Incidence of acute kidney injury (AKI) within the first 7 days as based on current Kidney Disease: Improving Global Outcomes (KDIGO) recommendation60 weeks
Need for renal replacement therapy (RRT) after admission to ICU60 weeks
Identification of an immunological fingerprint indicating multi-organ dysfunction60 weeksFlow cytometry
Incidence of acute kidney injury (AKI) within the first 48 hours as based on current Kidney Disease: Improving Global Outcomes (KDIGO) recommendation60 weeks

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026